Sputnik V vaccine efficacy confirmed at '91.4 per cent' during Phase 3 trials
Dec 14, 2020
Moscow [Russia], December 14 : The efficacy of the Sputnik V COVID-19 vaccine has been confirmed to be 91.4 per cent, based on data analysis of the final control point of clinical trials, announced the Gamaleya National Center of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF) on Monday.